Exact(3)
Regardless of survival, scores for the 23 participants were generally decreasing immediately following therapy escalation (p = 0.016).
Across all five methods used to estimate dose escalation, patients receiving etanercept had significantly lower rates of dose escalation (P < 0.001) than patients receiving adalimumab.
In addition, the ratio of isofuran concentrations to F2-isoprostane concentrations decreased from 2.56 ± 2.26 to 1.07 ± 0.56 during CoQ10 dose escalation (P = 0.01), a ratio similar to that observed in non-dialysis control subjects (1.53 ± 1.31, P =0.16).
Similar(57)
Further reflecting these changes in patient support, there was also a trend for scores to move from rising to falling at such treatment escalations (p = 0.024).
The 28-day mortality rate was 22.9% in patients with de-escalation compared with 36.0% in patients without de-escalation (P = 0.01).
Appropriate initial antibiotics were received by 32 patients (72.7%) in the de-escalation group and 63 patients (67.7%) in the non-de-escalation group (P = 0.55).
The rate of nonpneumonia infection during treatment of ICU-acquired pneumonia was 31.8% (14 of 44 patients) in the de-escalation group and 23.7% (22 of 93 patients) in the non-de-escalation group (P = 0.31).
The pneumonia-related mortality and overall mortality at day 30, however, was significantly lower in the de-escalation group (P = 0.03).
Finally, de-escalation had no impact on MDR bacteria carriage (15.3% in de-escalated patients versus 10.7% in non-de-escalated patients; P = 0.1).
The mean RR derived in the first 4-hours after admission is strongly associated with risk escalation patterns observed (p-value < 0.001), specifically, patients of "persistently high" type were more likely to have higher mean risk levels at SDU admission.
The pneumonia-related mortality rate was not significantly different in the de-escalation group compared to the non-de-escalation group at day 14 (P = 0.08).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com